ReviewAnnals of medicine and surgery (2012)2026
Evolution in lung IRI cell death research: a 20-year global bibliometric study (2005-2024).
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung ischemia-reperfusion injury (LIRI) is a central pathological mechanism underlying primary graft dysfunction after lung transplantation. Regulated cell death modalities - including apoptosis, ferroptosis, and pyroptosis - are increasingly recognized as key drivers of LIRI. However, research is fragmented, with shifting foci and limited integration of the overall knowledge structure. Methods: We retrieved 2462 English-language articles (2005-2024) from the Web of Science Core Collection and conducted a comprehensive bibliometric analysis using CiteSpace, VOSviewer, and Bibliometrix, examining publication trends, international collaborations, keyword co-occurrence, and co-citation networks. Results: The United States (941 publications) and China (809 publications) accounted for 71.1% of global output. Thematic evolution showed a transition from an early focus on "ischemia-reperfusion injury" and "inflammation" to mechanistic studies of "apoptosis" and "oxidative stress." Since 2020, emerging pathways such as "ferroptosis," "mitophagy," and "exosomes" have become prominent, with "ferroptosis" surging in 2022-2023 as a leading frontier. Co-citation analyses revealed that U.S. and Chinese research ecosystems drive experimental modeling and theoretical innovation, respectively, while cross-regional collaboration remains limited. Conclusions: LIRI research is shifting from classical inflammation-apoptosis paradigms toward a multidimensional, mechanistically nuanced framework. The dual-core structure of China and the United States, coupled with increasing integration of basic and clinical studies, highlights a growing convergence across organ systems. The data-driven knowledge map provided here offers a strategic reference for future translational and therapeutic research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.